Cargando…

Clinical utility of tumour mutational burden on efficacy of immune checkpoint inhibitors in malignant solid tumours: protocol for a systematic review and meta-analysis

INTRODUCTION: A major development in solid malignancy treatment is the application of immune checkpoint inhibitors (ICIs), which have produced durable responses and increased survival rates. However, the therapeutic effect of ICIs has great heterogeneity in patients with cancer. We propose a systema...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiang, Xuemei, Li, Yunming, Yang, Xiaoguang, Guo, Wang, Zhou, Pengfei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358952/ https://www.ncbi.nlm.nih.gov/pubmed/35926995 http://dx.doi.org/10.1136/bmjopen-2021-058692

Ejemplares similares

Safety and efficacy of autologous tumour cell vaccines as a cancer therapeutic to treat solid tumours and haematological malignancies: a meta-analysis protocol for two systematic reviews
por: Khan, Sarwat T, et al.
Publicado: (2020)

The cost burden of trastuzumab and bevacizumab therapy for solid tumours in Canada
por: Drucker, A., et al.
Publicado: (2008)

Heterogeneity of tumour mutational burden in metastatic NSCLC demonstrated by endobronchial ultrasound sampling
por: Leong, Tracy L., et al.
Publicado: (2023)

Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with IDH1-mutated or IDH2-mutated solid tumours
por: Molenaar, Remco J, et al.
Publicado: (2017)

A Retrospective Study of Brain Metastases From Solid Malignancies: The Effect of Immune Checkpoint Inhibitors
por: Du, Wei, et al.
Publicado: (2021)

Discussion of tumor mutation burden as an indicator to predict efficacy of immune checkpoint inhibitors: A case report
por: Wu, Mingrui, et al.
Publicado: (2022)

BESPOKE IO protocol: a multicentre, prospective observational study evaluating the utility of ctDNA in guiding immunotherapy in patients with advanced solid tumours
por: Kasi, Pashtoon Murtaza, et al.
Publicado: (2022)

Impact of panel design and cut-off on tumour mutational burden assessment in metastatic solid tumour samples
por: Mankor, Joanne M., et al.
Publicado: (2020)

Editorial: Tumour microenvironment heterogeneity in hematological malignancies
por: Deaglio, Silvia, et al.
Publicado: (2023)

Efficacy and safety of combination PD‐1/PD‐L1 checkpoint inhibitors for malignant solid tumours: A systematic review
por: Yao, Qigu, et al.
Publicado: (2020)

Next-Generation Sequencing Reveals High Uncommon EGFR Mutations and Tumour Mutation Burden in a Subgroup of Lung Cancer Patients
por: Guo, Gang, et al.
Publicado: (2021)

The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis
por: Wu, Yongfeng, et al.
Publicado: (2019)

Malignant tumours of the foot and ankle
por: Mascard, E., et al.
Publicado: (2017)

Case report: Successful use of mepolizumab for immune checkpoint inhibitors–induced hypereosinophilic syndrome in two patients with solid malignancies
por: Lazzari, Chiara, et al.
Publicado: (2023)

Editorial: The advances in proteomics and targeted therapy of malignant brain tumours
por: Chen, Anjing, et al.
Publicado: (2023)

Hyperprogressive disease in patients suffering from solid malignancies treated by immune checkpoint inhibitors: A systematic review and meta-analysis
por: Zhao, Zijun, et al.
Publicado: (2022)

Retinoic Acid Induces an IFN-Driven Inflammatory Tumour Microenvironment, Sensitizing to Immune Checkpoint Therapy
por: Tilsed, Caitlin M., et al.
Publicado: (2022)

Malignant Peripheral Nerve Sheath Tumour of the Forearm Presenting as Foreign Body
por: Arealis, Georgios, et al.
Publicado: (2021)

The utility of Ki-67 as a prognostic biomarker in pulmonary neuroendocrine tumours: protocol for a systematic review and meta-analysis
por: Naheed, Salma, et al.
Publicado: (2019)

Prognostic Role of Tumor Mutational Burden in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Huang, Taobi, et al.
Publicado: (2021)

Therapy of genomic unstable solid tumours (WHO grade 3/4）in clinical stage III/IV using individualised neoantigen tumour peptides-INP trial (individualised neoantigen tumour peptides immunotherapy): study protocol for an open-label, non-randomised, prospective, single-arm trial
por: Wang, Ling, et al.
Publicado: (2022)

The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China
por: Chen, Yanhui, et al.
Publicado: (2020)

Malignant mesothelioma tumours: molecular pathogenesis, diagnosis, and therapies accompanying clinical studies
por: Sahu, Ram Kumar, et al.
Publicado: (2023)

Solitary fibrous tumour of the urinary bladder – A rare and potentially malignant neoplasm
por: Ong, Katherine, et al.
Publicado: (2023)

Utility of 5-ALA for resection of CNS tumours other than high-grade gliomas: a protocol for a systematic review
por: Solomou, Georgios, et al.
Publicado: (2022)

Tracing the genetic fingerprints of tumour evolution: The pursuit of identifying mutations with differential weights within the overall tumour mutation burden and their role in therapeutic responses with immune checkpoint blockade
por: Niknafs, Noushin, et al.
Publicado: (2023)

Inadvertent excision of malignant soft tissue tumours
por: Grimer, Robert, et al.
Publicado: (2019)

A mathematical model for the quantification of a patient’s sensitivity to checkpoint inhibitors and long-term tumour burden
por: Butner, Joseph D, et al.
Publicado: (2021)

Hyperprogressive Disease (HPD) in Solid Tumours Receiving Immune Checkpoint Inhibitors in a Real-World Setting
por: Kanjanapan, Yada, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors and Opioids in Patients with Solid Tumours: Is Their Association Safe? A Systematic Literature Review
por: Cani, Massimiliano, et al.
Publicado: (2022)

Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends
por: Sun, Qian, et al.
Publicado: (2023)

Bias and inconsistency in the estimation of tumour mutation burden
por: Makrooni, Mohammad A., et al.
Publicado: (2022)

Clinicopathological and prognostic value of epithelial cell adhesion molecule in solid tumours: a meta-analysis
por: Ding, Peiwen, et al.
Publicado: (2023)

Study protocol for NeuroCARE: a randomised controlled trial of a psychological intervention for caregivers of patients with primary malignant brain tumours
por: Forst, Deborah Anne, et al.
Publicado: (2023)

Efficacy of Immune Checkpoint Inhibitors in Rare Tumours: A Systematic Review
por: Petrelli, Fausto, et al.
Publicado: (2021)

A Fast Protocol for Multiparametric Characterisation of Diffusion in the Brain and Brain Tumours
por: Loução, Ricardo, et al.
Publicado: (2021)

Detection and utility of cell-free and circulating tumour DNA in bone and soft-tissue sarcomas
por: Tsoi, Kim M., et al.
Publicado: (2021)

Platform study of genotyping-guided precision medicine for rare solid tumours: a study protocol for a phase II, non-randomised, 18-month, open-label, multiarm, single-centre clinical trial testing the safety and efficacy of multiple Chinese-approved targeted drugs and PD-1 inhibitors in the treatment of metastatic rare tumours
por: Wang, Shuhang, et al.
Publicado: (2021)

Case Report: Significant Response to Immune Checkpoint Inhibitor Camrelizumab in a Heavily Pretreated Advanced ER+/HER2− Breast Cancer Patient With High Tumor Mutational Burden
por: Wang, Rong, et al.
Publicado: (2021)

Management of BRCA Tumour Testing in an Integrated Molecular Tumour Board Multidisciplinary Model
por: Azzollini, Jacopo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_k3946p64uok5l70d9vtj9pueg4